New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review

Donzella, Denise; Bellis, Elisa; Campisi, Paola; Crepaldi, Gloria; Data, Valeria; Dapavo, Paolo; Lomater, Claudia; Marucco, Elena; Saracco, Marta; Gatto, Mariele; Iagnocco, Annamaria

doi:10.1016/j.autrev.2023.103481

Autoimmunity Reviews

2024

DOI: 10.1016/j.autrev.2023.103481

|View full text |Cite

New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review

Denise Donzella,

Elisa Bellis,

Paola Campisi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Certolizumab-induced sarcoidosis in a patient with psoriatic arthritis – a case report and review of literature

Biernikowicz,

Pilch,

Wojturska

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

Tumour necrosis factor-α (TNF- α) antagonists are considered a significant therapeutic option in the treatment of sarcoidosis. Nevertheless, their use can also paradoxically result in sarcoidosis-like reactions. Here, we present a case of a 56-year-old patient with psoriatic arthritis who after 3 months of certolizumab therapy developed pulmonary sarcoidosis. Therefore, certolizumab was discontinued and prednisone initiated. Subsequently, 4 months later a complete remission of interstitial lesions was observed. Due to insufficient control of psoriatic arthritis, upadacitinib and methotrexate were prescribed and despite initial improvement, a couple of months later a massive exacerbation of skin psoriasis occurred and the treatment was switched to secukinumab. As of today, no evidence of sarcoidosis recurrence has been noted. Drug-induced sarcoidosis-like reactions (DISR) appear to be less frequently associated with certolizumab rather than with other anti-TNF-α agents. However, specific mechanisms of this phenomenon remain unclear and require future investigation.

show abstract

Certolizumab-induced sarcoidosis in a patient with psoriatic arthritis – a case report and review of literature

Biernikowicz,

Pilch,

Wojturska

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

show abstract

Certolizumab pegol/Golimumab/Secukinumab

2024

Reactions Weekly

View full text Add to dashboard Cite

Rheumatic Manifestations of Sarcoidosis

Day,

Hamann

2024

Diagnostics

View full text Add to dashboard Cite

Sarcoidosis is a multisystem granulomatous inflammatory disorder, of unknown aetiology, which causes a wide spectrum of clinical phenotypes. It can present at any age, most commonly between 20 and 60 years, with a roughly equal sex distribution. Diagnosis is often delayed due to multiple diagnostic mimics, particularly joint disease. Common presenting features include pulmonary disease, with bilateral hilar lymphadenopathy and pulmonary infiltrates, cutaneous lesions, and ocular disease. Musculoskeletal manifestations are reported in 10–40% of patients with sarcoidosis and include bone lesions, acute arthritis, chronic arthritis, axial disease, dactylitis, and sarcoid myopathy, which are explored in detail in this review article. Diagnosis is confirmed through histological evidence of non-caseating granuloma on tissue biopsy. Newer imaging modalities, including 18FFDG PET/CT, can help identify the extent of musculoskeletal involvement, and biomarkers can provide weight to a diagnosis, but there is no single biomarker with prognostic value for disease monitoring. The mainstay of treatment remains corticosteroids, followed by disease-modifying antirheumatic drugs such as methotrexate and antimalarials. More recently, biologic treatments have been used successfully in the treatment of sarcoidosis with rheumatic involvement.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review

Cited by 3 publications

References 45 publications

Certolizumab-induced sarcoidosis in a patient with psoriatic arthritis – a case report and review of literature

Certolizumab-induced sarcoidosis in a patient with psoriatic arthritis – a case report and review of literature

Certolizumab pegol/Golimumab/Secukinumab

Rheumatic Manifestations of Sarcoidosis

Contact Info

Product

Resources

About